The strong durability and magnitude of response at 36 weeks in the highest dose cohort support the potential of EP-104GI as a best-in-class, single-administration therapy for EoE. Traders should monitor the Q4 2026 top-line data from the Phase 2b placebo-controlled trial as the next major catalyst, which will provide statistically powered evidence of efficacy and could drive significant valuation inflection.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals released 36-week data from the highest dose cohort (Cohort 9, n=3) in the open-label Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE), showing robust and sustained improvements in both tissue health and symptom response, with 90% and 88% reductions in EoEHSS Stage and Grade, a 72% reduction in Peak Eosinophil Count, and 66% of patients maintaining clinical remission. The drug continues to show a strong safety profile with no drug-related serious adverse events or oropharyngeal candidiasis across 31 patients and over 230 patient-months of follow-up.
Key Facts
- Cohort 9 (n=3) showed 90% and 88% reduction in EoEHSS Stage and Grade at week 36, the highest response across all cohorts.
- 72% reduction in Peak Eosinophil Count (PEC) from baseline, the largest reduction observed.
- 66% of patients (2 of 3) maintained clinical remission (≥3-point reduction in SDI) from week 8 through week 36.
- No drug-related serious adverse events (SAEs); no cases of oropharyngeal candidiasis, adrenal insufficiency, or glucose derangement reported.
- 31 patients treated across all cohorts with over 230 patient-months of follow-up; drug well tolerated at all doses.
- Phase 2b placebo-controlled trial of EP-104GI (120mg and 160mg doses) is ongoing, with top-line data expected in Q4 2026.
Financial Impact
No direct financial impact from this data release, but the positive clinical results increase the probability of success in the upcoming Phase 2b trial, potentially enhancing the value of EP-104GI and improving fundraising or partnership prospects.
Risk Factors
- Small sample size in Cohort 9 (n=3) limits statistical significance and generalizability.
- Open-label design introduces potential bias; placebo-controlled Phase 2b results may differ.
- Future regulatory or clinical setbacks could occur despite current positive data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002597 |
| Document: f6k_042126.htm | 0001171843-26-002597 |
| Document: 0001171843-26-002597-index-headers.html | 0001171843-26-002597 |
| Document: 0001171843-26-002597-index.html | 0001171843-26-002597 |
| Document: 0001171843-26-002597.txt | 0001171843-26-002597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers